Profile data is unavailable for this security.
About the company
Albert David Limited is engaged in manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. The Company offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. It has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.
- Revenue in INR (TTM)3.62bn
- Net income in INR754.20m
- Incorporated1938
- Employees1.27k
- LocationAlbert David Ltd15, Chittaranjan Avenue, 2nd FloorKOLKATA 700001IndiaIND
- Phone+91 3 322302330
- Fax+91 3 322628439
- Websitehttps://www.albertdavidindia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wanbury Ltd | 5.69bn | 233.39m | 5.16bn | 1.58k | 22.12 | -- | 14.26 | 0.906 | 7.12 | 7.12 | 173.80 | -- | -- | -- | -- | 3,598,099.00 | -- | 6.56 | -- | -- | 46.15 | 43.92 | 4.10 | 4.54 | -- | 1.82 | -- | -- | -2.26 | 5.95 | -112.76 | -- | 34.73 | -- |
| ZIM Laboratories Ltd | 3.67bn | 172.46m | 5.48bn | 525.00 | 31.81 | 2.30 | 16.51 | 1.49 | 3.54 | 3.54 | 75.34 | 49.00 | 0.9321 | 2.54 | 3.76 | -- | 4.38 | 3.88 | 6.66 | 6.54 | 53.34 | 48.30 | 4.69 | 3.97 | 0.9182 | 3.67 | 0.3131 | -- | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Kilitch Drugs (India) Ltd | 1.55bn | 145.71m | 5.49bn | 153.00 | 37.04 | -- | 34.03 | 3.54 | 9.21 | 9.21 | 98.24 | -- | -- | -- | -- | 10,132,730.00 | -- | 2.63 | -- | 3.59 | 39.68 | 33.85 | 8.25 | 5.01 | -- | 3.43 | -- | 2.93 | 22.20 | 22.30 | 41.82 | 15.19 | 1.79 | -- |
| Valiant Laboratories Ltd | 1.82bn | 3.40m | 6.31bn | -- | 345.60 | 2.66 | 275.60 | 3.46 | 0.42 | 0.42 | 49.55 | 54.51 | -- | -- | -- | -- | -- | -- | -- | -- | 7.58 | -- | 0.187 | -- | 7.41 | -133.11 | 0.2446 | -- | -45.48 | -- | -98.83 | -- | -- | -- |
| IND Swift Laboratories Ltd | 12.81bn | 3.07bn | 6.52bn | 1.50k | 2.12 | 0.6997 | 1.81 | 0.5088 | 51.99 | 51.99 | 216.90 | 157.64 | 0.857 | 3.45 | 3.80 | -- | 20.58 | 5.00 | 25.67 | 6.13 | 39.47 | 42.82 | 24.02 | 8.52 | 2.94 | 1.70 | 0.0175 | -- | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Medicamen Biotech Ltd | 1.71bn | 126.93m | 6.73bn | 388.00 | 54.14 | -- | 37.06 | 3.95 | 9.78 | 9.78 | 131.89 | -- | -- | -- | -- | 4,398,250.00 | -- | 7.17 | -- | 10.44 | 46.88 | 33.85 | 6.58 | 10.87 | -- | 4.76 | -- | 8.61 | 22.02 | 4.77 | -0.3555 | 7.98 | -4.21 | 0.00 |
| Albert David Ltd | 3.62bn | 754.20m | 6.74bn | 1.27k | 8.93 | 1.76 | 8.19 | 1.86 | 132.16 | 132.16 | 635.16 | 671.05 | 0.7868 | 2.67 | 12.15 | -- | 16.37 | 10.00 | 20.85 | 13.15 | 65.30 | 61.03 | 20.81 | 11.87 | 3.31 | 124.70 | 0.0086 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Sakar Healthcare Ltd | 1.51bn | 124.73m | 7.52bn | 297.00 | 56.65 | -- | 25.73 | 4.98 | 6.10 | 6.10 | 73.58 | -- | -- | -- | -- | 5,082,286.00 | -- | 6.35 | -- | 7.59 | 46.18 | 44.28 | 8.26 | 10.84 | -- | 2.40 | -- | -- | 4.00 | 20.23 | -16.30 | 27.31 | 56.31 | -- |
| Nectar Lifesciences Ltd | 16.86bn | 49.95m | 7.57bn | 1.59k | 146.74 | 0.7079 | 11.52 | 0.449 | 0.23 | 0.23 | 79.16 | 47.68 | 0.7697 | 1.74 | 5.12 | -- | 0.228 | -0.2956 | 0.3969 | -0.541 | 28.68 | 18.39 | 0.2963 | -0.4052 | 0.5907 | 1.06 | 0.3728 | -- | 10.63 | -9.54 | 120.65 | -36.29 | -5.06 | -- |
| Panacea Biotec Ltd | 5.52bn | -119.17m | 8.39bn | 1.09k | -- | -- | 16.30 | 1.52 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
| Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.44bn | 1.06k | 39.68 | -- | 17.23 | 1.70 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
| Holder | Shares | % Held |
|---|---|---|
| General Insurance Corp. of India (Invt Port)as of 31 Dec 2023 | 93.92k | 1.65% |
